Cilomilast: Orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease

Annals of Pharmacotherapy

Volumn 40, Issue 10, 2006, Pages 1822-1828

  Martina, Shaunta D ^a   Ismail, Maha S ^a   Vesta, Kimi S ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Chronic obstructive pulmonary disease; Cilomilast; Selective phosphodiesterase 4 inhibitor

Indexed keywords

CILOMILAST; IPRATROPIUM BROMIDE; PHOSPHODIESTERASE IV; PLACEBO; SALBUTAMOL;

BRONCHOSPASM; BRONCHUS MUCUS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LUNG FUNCTION; MEDLINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCISEARCH;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, ORAL; CARBOXYLIC ACIDS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOHEXANECARBOXYLIC ACIDS; HUMANS; NITRILES; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 33749645845     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H049     Document Type: Review

References (17)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda, MD: World Health Organization/National Heart, Lung and Blood Institute, 2005. www.goldcopd.com (accessed 2006 Jan 4).
2. The National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(suppl 1):i1-i232.
3. Torphy TJ, Barnette MS, Underwood DC, et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999; 12:131-5.
4. Soto FJ, Hanania NA. Selective phosphodiesterase- 4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med 2005;11:129-34.
5. Sturton G, Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest 2002;121:192-6.
6. Mata M, Sarria B, Buenestado A, Cortigo J, Cerda M, Morcillo EJ. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 2005;60:144-52.
7. Profita M, Chiappara G, Mirabella F, et al. Effect of cilomilast (Ariflo) on TNF-α, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 2003;58:573-9.
8. Zussman BD, Davie CC, Kelly J, et al. Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast. Pharmacotherapy 2001; 21:653-60.
9. Zussman BD, Benincosa LJ, Webber DM, et al. An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers. J Clin Pharmacol 2001;41:950-8.
10. Rennard SI, Schachter N, Strek M, Rickard K, Amit O. Cilomilast for COPD. Results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006;129:56-66.
11. Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomized, dose-ranging study. Lancet 2001; 358:265-70.
12. Grootendorst DC, Gauw SA, Baan R, et al. Does a single dose of the phosphodiesterase 4 inhibitor cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease? Pulm Pharmacol 2003;16:115-20.
13. Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168: 976-82.
14. Murdoch RD, Cowley H, Kelly J, Higgins R, Webber D. Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol. Pulm Pharmacol Ther 2002;15:521-7.
15. Murdoch RD, Zussman B, Schofield JP, Webber DM. Lack of pharmacokinetic interactions between cilomilast and theophylline or smoking in healthy volunteers. J Clin Pharmacol 2004;44:1046-53.
16. Kelly J, Murdoch RD, Clark DJ, Webber DM, Fuder H. Warfarin pharmacodynamics unaffected by cilomilast. Ann Pharmacother 2001;35:1535-9. DOI 10.1345/aph.10369.
17. Zussman BD, Kelly J, Murdoch RD, Clark DJ, Schubert C, Collie H. Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin. Clin Ther 2001;23:921-31.